Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche ...

Hello, and welcome, everyone, to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky, and I'll be your operator today. (Operator Instructions) I will now hand over to your host, Head of ...